CMS proposes faster prior authorization rules for prescription drugs
CMS has proposed new rules aimed at speeding up prior authorization for prescription drugs and making the process more transparent for patients and clinicians. The changes are not final yet, but they could affect several major coverage groups if adopted.
Patients who rely on covered medicines may eventually see a faster, more digital prior-authorization process. In April 2026, the Centers for Medicare & Medicaid Services proposed new rules that would extend electronic prior authorization to prescription drugs and set shorter decision deadlines for many CMS-regulated health plans.
The proposal is not final, so nothing changes right away. If adopted, it could affect people with Medicare Advantage, Medicaid managed care, Medicaid fee-for-service coverage, CHIP, Affordable Care Act marketplace plans, and some small-group plans on the federal SHOP marketplace.
What CMS proposed
CMS says the goal is to make prior authorization for drugs more expeditious, transparent, and reliable. The agency proposed electronic systems for drug requests, clearer deadlines for decisions, and more public reporting on approval and denial patterns. CMS also said the changes would build on earlier interoperability rules that already covered non-drug items and services.
What prior authorization is
Prior authorization is a health plan review process that asks for approval before it will cover certain drugs or services. Plans use it to check medical necessity and coverage rules, but it can also slow access when paperwork is incomplete or the process is hard to navigate. KFF says patients and clinicians often struggle to know what requires approval, what criteria are used, and how long the process will take.
Which coverage groups could be affected
Under the proposal, CMS would extend drug prior-authorization requirements to Medicare Advantage plans; Medicaid managed care plans; Medicaid fee-for-service programs; CHIP managed care and fee-for-service coverage; Qualified Health Plans on the federally facilitated marketplace; and small-group plans on the federal SHOP marketplace. CMS said the proposal also would extend certain interoperability requirements to drug coverage under medical benefits and pharmacy benefits.
What would change if the rule is finalized
The proposal would require affected payers to support electronic prior authorization for drugs, with standards that let providers check formulary and coverage information in real time and submit requests electronically. CMS also proposed shorter decision timeframes. For some drug requests, Medicaid and CHIP plans would generally need to respond within 24 hours, while federal marketplace plans would need to respond no later than 72 hours for standard requests and 24 hours for expedited requests. CMS also proposed requiring certain plans to give a specific reason when denying a drug prior authorization request.
CMS said it also wants plans to report more information about prior authorization, including approval and denial rates, appeal outcomes, and decision timeframes. KFF has noted that current public reporting is limited and often does not show enough detail to explain why requests are approved or denied.
What is still uncertain
This is still only a proposal. CMS has not finalized the rule, and the agency could change the details after public comment. Many of the proposed compliance dates begin October 1, 2027, if the rule is finalized. Until then, current plan rules remain in place.
How this could affect patients, caregivers, and clinicians
If the proposal becomes final, patients might experience fewer delays when starting a covered medicine. Caregivers could face less back-and-forth with plan paperwork. Clinicians and pharmacies could spend less time faxing forms or chasing coverage information if electronic systems work as intended. Even so, the actual experience will still depend on the health plan, the drug, and whether a request is routine or urgent.
What readers can do now
For now, patients should keep using their current plan’s prior-authorization process and should not assume the rules have changed. If a medicine is delayed, ask the plan, prescriber, or pharmacy what information is missing and whether an appeal is possible. People with Medicare, Medicaid, marketplace coverage, or employer coverage should also check their own plan documents, because requirements can vary by insurer and state.
For clinicians and office staff, CMS is signaling that electronic prior authorization is likely to remain a direction of federal rulemaking, so this may be a good time to review workflow readiness with EHR vendors and plan partners. For families, the main takeaway is simple: this proposal is meant to reduce avoidable delay, but it is not yet an active guarantee of faster coverage decisions.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
